Pfizer Macugen, C0X-2 Updates Expected At Nov. 30 Analyst Meeting
This article was originally published in The Pink Sheet Daily
The meeting is expected to focus on Pfizer's pipeline, including the inhaled insulin Exubera and insomnia agent indiplon. Pfizer will likely discuss safety profile of its COX-2 inhibitors.
You may also be interested in...
FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx
FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.
Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.